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provides an excellent LC. However, despite good local 
control we observed a crude distant metastasis rate of 25% in 
N2 disease, suggesting a need for novel chemotherapeutic 
approaches to improve systemic control in these patients. OS 
was significantly influenced by T staging (p=0.035), 
suggesting the need for dose escalation in patients with 
higher T-stage (cT3-T4). Therefore, further studies are 
warranted to evaluate if dose escalation to both gross tumor 
and areas of potential nodal spread can improve LC and OS. 
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Purpose/Objective: Intra luminal brachytherapy (ILBT) is 
utilised for oesophageal cancer as a palliative treatment with 
the aim to improve and maintain patients’ swallowing 
function and delaying or avoiding the need for an 
endoluminal oesophageal stent. It is utilised as a boost 
treatment following external beam radiotherapy in patients’ 
deemed unsuitable for definitive chemoradiation or high dose 
external beam treatments; or as salvage treatment for those 
with relapsed disease more than 6 months from external 
beam treatment.Treatment was delivered either as a single 
8Gy dose to the PTV or 14-16 Gy in 2 fractions a maximum of 
1 week apart. In this retrospective analysis, we evaluate the 
outcomes of patients treated with ILBT in West Yorkshire 
over a 4 year period.  
Materials and Methods: Information collected from entries in 
the Leeds oesophageal brachytherapy database and patient 
pathway manager (clinical data software). Data on basic 
patient/tumour demographics, date of treatment, 
dose/fractionation schedule of treatment, brachytherapy 
dosimetric data, toxicity profile, swallowing assessment 
before and after treatment and date of subsequent 
oesophageal stent (if needed) was reviewed.  
All ILBT treatments were 3D CT conformal planned  
Results: A total of 33 patients have been treated between 
April 2010 and August 2014. The median performance status 
was one. 21patients (64%) patients had a single treatment. 
Most treatments (76 %) were given as boost following 30Gy in 
10 fractions of external beam radiotherapy. 27% of patients 
required subsequent oesophageal stent insertion for 
palliation of critical dysphagia. The median overall survival 
was 211 days whilst the median stent free survival was 204 
days. 6% of patients had documented grade 3 RTOG toxicity, 
related to dysphagia. There were no treatment related 
bleeding or perforation events. The median PTV volume was 
38.3cm3 with the median maximum diameter for each PTV 
38.0mm. Mean PTV V100 was 81.9%(+/-15.2%, 1SD), and V200 
of 38.1%(+/- 13.2%, 1SD). Mean PTV D90 was 6.4Gy(+/- 
1.5Gy, 1SD) and Mean GTV D90 was 7.2Gy(+/- 1.3%, 1SD) for 
each fraction. The spinal cord mean D2cc (maximum dose for 
2cc volume of spinal cord) was 1.1Gy(+/- 0.5Gy, 1SD) whilst 
the mean D0.1cc was 1. 5Gy(+/- 0.6Gy, 1Sd). 
Conclusions: Intra luminal oesophageal brachytherapy is a 
safe and effective method of delivering palliative 
radiotherapy for patients with oesophageal cancer where 
other radical treatments are deemed inappropriate. It is well 
tolerated and can delay or eliminate the need for 
oesophageal stents for symptomatic dysphagia. Further study 
in to the role of using sequential ILBT with removable stents 
to maintain swallowing function is required.  
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Purpose/Objective: Standard treatment for locally advanced 
rectal cancer is neoadjuvant fluoropyrimidine-based 
chemoradiotherapy (CRT) followed by total mesorectal 
excision. Research has been focused on intensifying 
neoadjuvant treatment. This systematic review evaluated 
Phase II treatment intensification trials. 
Materials and Methods: A systematic search of the PubMed, 
EMBASE, MEDLINE and the Cochrane Library databases was 
performed from January 2004 to September 2014 for all 
published Phase II trials of neoadjuvant treatment 
intensification in locally advanced rectal cancer. Eighty-one 
eligible Phase II trials were identified from 474 articles. For 
each trial, clinical, methodological and statistical 
components were assessed. 
Results: Ninety-one experimental arms from 81 trials were 
identified. Median number of patients recruited per trial was 
50 (range: 8–279) over a median recruitment period of 26 
months (range: 4–108). Eighty-three arms studied CRT 
intensification: 36(36.6%) additional cytotoxic, 10(11.0%) 
additional biological agent, 3(3.3%) additional radiosensitiser, 
16(17.6%) radiotherapy dose intensification, and 18(19.8%) a 
combination of agents. Neoadjuvant chemotherapy was 
added in 22 experimental arms (14 arms alongside CRT 
intensification): 7(7.7%) additional cytotoxic, 1(1.1%) 
additional biological agent and 6(6.6%) a combination of 
agents. 
Only nine trials were randomised of which five had a 
standard control arm. Twenty studies did not report a 
sample size calculation and only 44(54.3%) studies stated 
their statistical trial design. Fifteen differently defined 
primary endpoints were stated in 73 studies. Seventy-six 
trials recruited both AJCC stage II and III disease. MRI local 
staging was mandated in 35 trials while the circumferential 
resection margin was assessed in only 10 trials. Only 31 of the 
81 studies were rated to have a good overall statistical design 
and compliance. No meta-analysis could be performed due to 
trial heterogeneity. 
Conclusions: The very small number of randomised phase II 
trials, the lack of agreement regarding useful primary end 
points and the poor clinical trial design quality are major 
concerns. These factors are likely to be a major contributor 
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to the very slow progress in evaluating novel neoadjuvant 
strategies in rectal cancer. 
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Purpose/Objective: This study was planned to clarify the 
optimal treatment for squamous cell carcinoma of the 
rectum, an histological entity extremely rare. 
Materials and Methods: The analysis includes 8 patients 
treated in the Radiotherapy Department of 'Università 
Sapienza di Roma' and 'Università Cattolica del Sacro Cuore di 
Roma'. Patients, retrospectively reviewed, were affected by 
histologically proven rectal squamous cell carcinoma, without 
any distant metastases, any anal canal extension and any 
fistulous tract. Due to the histological nature of the tumour, 
patients were staged according to AJCC TNM Staging System 
2010 for anal squamous cell carcinoma: 3 patients were 
clinically staged as IIIA (perirectal lymph nodes), 3 patients 
as IIIB (unilateral iliac and/or inguinal lymph node) and 2 
patients as II. All patients received definitive concomitant 
radiochemotherapy (RT-CHT). Radiation therapy was 
delivered with a 3D-conformational multiple field technique 
to a dose ranging from 45 to 76.5 Gy, with 6 - 15 MV energy 
photons. Target volume included primary tumor, mesorectal 
and posterior pelvic subsite, and regional node (internal and 
external iliac, presacral, obturator, inguinal lymph nodes). 
Chemotherapy consisted of an antimetabolite drug (5-
Fluorouracile or Raltitrexed) in association with mitomycin C 
or oxaliplatin.  
Results: All patients completed programmed RT-CHT 
treatment. Severe acute toxicity by RTOG scale was not 
recorded. All patients developed mild (G1) to moderate (G2) 
gastrointestinal toxicity, as well as a perineal skin reaction ≤ 
G2. Six months after the end of treatment, 7 patients (87.5 
%) showed a tumour regression, both complete (n = 6) and 
partial (n = 1). One patients presented persistent disease and 
underwent salvage surgery.  With a mean follow-up of 41.75 
months, 7 patients are still a disease free survivors and 
preserving anus and rectum. Only 1 patient developed local 
recurrence at 6 months and he died 14 months after 
abdomino-perineal resection. 
Conclusions: Primary RT-CHT, with a curative intent, should 
be considered the treatment modality of choice for squamous 
carcinoma of the rectum. As for the anal carcinoma, surgery 
should have a limited place in the initial management of this 
disease. In the squamous cell carcinoma of the rectum, 
surgery has to be used only with salvage intent. High dose 
radiation therapy and concomitant chemotherapy regime as 
for anal canal tumor could guarantee a complete control of 
disease. 
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Purpose/Objective: The frequency of cases of resectable 
pancreatic cancer is less than 20%. Locally advanced diseases 
about 30% of all cases, and in 50% of cases the disease has 
metastases.The average life expectancy in resected patients 
only after surgical treatmentis an average of 12 – 13 months. 
Low life expectancy, poor treatment efficacy, duration and 
tolerability of heavy teletherapy course force radiologists to 
look for other options to help patients with pancreatic 
cancer. SBRT(Stereotactic Body Radiation Therapy) is a new 
method of treatment for these patients. In RCRC named after 
N.N. Blokhin has developed a methodology of SBRT using 
intensity modulated arches, with 7.5 Gy per fraction, 5 times 
a week, up to 37.5 Gy under the control of the imaging 
(IGRT). The aim of this study is to evaluate the efficacy and 
safety of stereotactic radiotherapy for pancreatic cancer in 
patients who have been denied an alternative treatments. 
Materials and Methods: From 2010 to 2013 SBRT with 
intensity modulated arches has been performed in 8 patients 
with pancreatic cancer. In 7 of 8 patients tumor was 
localized in the head of the pancreas, and 1 patient had loss 
of body and tail of the pancreas. Indifferent periods (1 - 3 
years) 4 patients who had radical surgery gained local 
recurrence of the disease. In 4 patients after palliative 
surgery and chemotherapy continued growth and further 
metastasis process was observed. All 8 patients had a course 
of stereotactic body radiotherapy (SBRT) under the control of 
the visualization (IGRT) using VMAT technique (RapidArc) on 
electron accelerator Varian Clinac 2300iX, multileaf 
collimator Milenium 120 and dynamic wedge filters, 6 MeV 
photon energy. Verification of the plan was performed using 
Cone-Beam CT and X-ray images in kilovolt beam. The dose 
was 7,5 Gy perfraction, up to 37,5 Gy. 
 
 
 
